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The standard treatment for KD is high-dose intravenous immunoglobulin (IVIG), manufactured from normal human immunoglobulin purified from the full plasma of a thousand healthy donors; it reduces the duration of fever and the incidence of coronary artery abnormalities. The anti-inflammatory effects of IVIG are manifested in a wide range of pathological conditions, including immune thrombocytopenia, systemic lupus erythrematosus, Guillain-Barré syndrome, and others. Despite IVIG therapy, however, ≈15% of patients with KD have persistent or recurrent fever with a high risk for coronary artery lesions. In our KD patients data, we also observed significant differences in clinical variables between IVIG responders (n=832) and nonresponders (n=147), where the latter group showed more severe inflammation and poorer clinical outcomes, including a longer duration of fever days (median 6.0 versus 8.0 days; P=8.99×10 -16 ), higher C-reactive protein levels (median 6.6 versus 10.9 mg/L; P=2.02×10 -8 ), and a higher ratio of coronary artery lesions (23.6% versus 39.5%; P=3.35×10 -5 ). Despite the clinical differences between responders and nonreponders, the genetic risk factors determining treatment responsiveness have not been studied.
To identify the IVIG response-specific genetic variants associated with KD, we initially performed an IVIG response-stratified genome-wide association study, using our previous data from 296 cases (196 IVIG responders and 100 IVIG nonresponders) and 1000 control subjects genotyped with the Illumina Omni1-Quad BeadChip as described in our previous study. 1 For replication study, we selected 40 IVIG response-specific candidate single nucleotide polymorphisms (SNPs) considering their P values (P<0.001 in 1 subgroup and P>0.30 in another subgroup) and their immune-related functions and tested them in an independent sample set consisting of 697 patients with KD (650 IVIG responders and 47 IVIG nonresponders) and 3553 control subjects. Genotyping for the replication study in the additional 697 patients with KD was performed using the Fluidigm SNPType assay platform (Fluidigm Corp, San Francisco, CA). This process identified an intronic SNP (rs3789065) in the BCL2L11 gene that showed a significant association with KD in IVIG responders (odds ratio=1.42; P=8.94×10 -11 ) but not in nonresponders (odds ratio=1.06; P=0.654; Table) . This suggests that BCL2L11 may play a role as a KD susceptibility gene in responders. By power calculation using CaTs program (http://csg.sph.umich.edu/abecasis/CaTS/), we found that our study has 85.4%, BCL2L11 (Bcl-2-like protein 11), a member of proapoptotic BH3-only protein in the Bcl-2 family that encodes the Bcl-2 interacting protein, is highly expressed in the immune system, including in bone marrow, and lymph nodes (http://www.proteinatlas.org/ ENSG00000153094-BCL2L11/tissue). In murine models, the loss of BCL2L11 can lead to the survival of autoreactive B cells and T cells that are likely to contribute to the development of autoimmune disease. 3 This indicates that BCL2L11 plays a critical role in regulating the homeostasis of lymphocytes. Interestingly, it has been previously reported that the KD-associated intronic SNP (rs3789065) in BCL2L11 is associated with serum concentrations of inflammation-associated complement component 3 peptide (HWESASXX), 4 and a risk allele (C allele) of a KD-associated SNP (rs3789065) showed significantly reduced expression of the BCL2L11 gene in human peripheral blood monocytes (P=4.23×10 -20 ). 5 These data suggest that the allele-specific reduced gene expression of BCL2L11 results in high susceptibility in IVIG responders.
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In conclusion, we have identified an intronic SNP (rs3789065) in BCL2L11 which is significantly associated with KD at the genome-wide significance level in IVIG responders but not in nonresponders. These findings provide new insights into KD susceptibility in patients with KD with IVIG responsiveness. 
